Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections

Trends in Pharmacological Sciences

Volumn 37, Issue 3, 2016, Pages 231-241

  Sause, William E ^a   Buckley, Peter T ^b   Strohl, William R ^b   Lynch, A Simon ^b   Torres, Victor J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

antibody; biologics; immune evasion; infectious diseases; MRSA

Indexed keywords

ALTASTAPH; AUROGRAB; MEDI 4893; PAGIBAXIMAB; POLYCLONAL ANTIBODY; SAR 279356; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; VERONATE; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; ANTIBODY TITER; BACTEREMIA; BACTERIAL COLONIZATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEWBORN INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; ANIMAL; IMMUNOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84958769064     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.11.008     Document Type: Review

References (80)

1. R. Dantes, and et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections United States, 2011 JAMA Intern. Med. 173 2013 1970 1978
2. N.J. Verkaik, and et al. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus J. Infect. Dis. 199 2009 625 632
3. A. Dryla, and et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients Clin. Diagn. Lab. Immunol. 12 2005 387 398
4. S. Holtfreter, and et al. Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis J. Infect. Dis. 193 2006 1275 1278
5. A.N. Spaan, and et al. Neutrophils versus Staphylococcus aureus: a biological tug of war Annu. Rev. Microbiol. 67 2013 629 650
6. V. Thammavongsa, and et al. Staphylococcal manipulation of host immune responses Nat. Rev. Microbiol. 13 2015 529 543
7. I.L. Scully, and et al. Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine Front. Immunol. 5 2014 109
8. V.G. Fowler Jr, and R.A. Proctor Where does a Staphylococcus aureus vaccine stand? Clin. Microbiol. Infect. 20 Suppl. 5 2014 66 75
9. K.U. Jansen, and et al. Vaccine review: 'Staphyloccocus aureus vaccines: problems and prospects' Vaccine 31 2013 2723 2730
10. R.S. Daum, and B. Spellberg Progress toward a Staphylococcus aureus vaccine Clin. Infect. Dis. 54 2012 560 567
11. W. Salgado-Pabon, and P.M. Schlievert Models matter: the search for an effective Staphylococcus aureus vaccine Nat. Rev. Microbiol. 12 2014 585 591
12. D.K. Benjamin, and et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin J. Perinatol. 26 2006 290 295
13. A.I. Fattom, and et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge Infect. Immun. 64 1996 1659 1665
14. I. Verdier, and et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests J. Clin. Microbiol. 45 2007 725 729
15. J.L. Cocchiaro, and et al. Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus Mol. Microbiol. 59 2006 948 960
16. S. Boyle-Vavra, and et al. USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus MBio 6 2015 e02585
17. M. DeJonge, and et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants J. Pediatr. 151 2007 260 265
18. J.H. Vernachio, and et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo Antimicrob. Agents Chemother. 50 2006 511 518
19. A.E. Hall, and et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A Infect. Immun. 71 2003 6864 6870
20. J.M. Patti A humanized monoclonal antibody targeting Staphylococcus aureus Vaccine 22 Suppl. 1 2004 S39 S43
21. J.J. Weems Jr, and et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia Antimicrob. Agents Chemother. 50 2006 2751 2755
22. J.F. John Jr Drug evaluation: tefibazumab - a monoclonal antibody against staphylococcal infection Curr. Opin. Mol. Ther. 8 2006 455 460
23. L.E. Weisman, and et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates Antimicrob. Agents Chemother. 53 2009 2879 2886
24. L.E. Weisman, and et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis Pediatrics 128 2011 271 279
25. Anon. Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis ClinicalTrials gov 2011 (https://clinicaltrials.gov/ct2/show/NCT00646399?term=pagibaximab&rank=1)
26. J.P. Burnie, and et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections Infect. Immun. 68 2000 3200 3209
27. M. Otto Novel targeted immunotherapy approaches for staphylococcal infection Expert Opin. Biol. Ther. 10 2010 1049 1059
28. M. Baker Anti-infective antibodies: finding the path forward Nat. Biotechnol. 24 2006 1491 1493
29. Sanofi A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation 2012 Sanofi
30. B.J. Berube, and J. Bubeck Wardenburg Staphylococcus aureus alpha-toxin: nearly a century of intrigue Toxins (Basel) 5 2013 1140 1166
31. J. Bubeck Wardenburg, and O. Schneewind Vaccine protection against Staphylococcus aureus pneumonia J. Exp. Med. 205 2008 287 294
32. A.D. Kennedy, and et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model J. Infect. Dis. 202 2010 1050 1058
33. M.E. Powers, and et al. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin J. Infect. Dis. 206 2012 352 356
34. G.R. Sampedro, and et al. Targeting Staphylococcus aureus alpha-toxin as a novel approach to reduce severity of recurrent skin and soft-tissue infections J. Infect. Dis. 210 2014 1012 1018
35. V. Oganesyan, and et al. Mechanisms of neutralization of a human anti-alpha-toxin antibody J. Biol. Chem. 289 2014 29874 29880
36. L. Hua, and et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia Antimicrob. Agents Chemother. 58 2014 1108 1117
37. Aridis Pharmaceuticals AR-301: Fully Human mAb Against Staphylococcus aureus 2015 Aridis Pharmaceuticals
38. Xbiotech MRSA 2015 iXbiotech
39. N.A. Kuklin, and et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model Infect. Immun. 74 2006 2215 2223
40. V.G. Fowler, and et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial JAMA 309 2013 1368 1378
41. C. Pozzi, and et al. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens PLoS ONE 7 2012 e46648
42. A.I. Fattom, and et al. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials Vaccine 22 2004 880 887
43. S. Romero-Steiner, and et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae Clin. Diagn. Lab. Immunol. 10 2003 1019 1024
44. A.L. DuMont, and et al. Identification of a crucial residue required for Staphylococcus aureus LukAB cytotoxicity and receptor recognition Infect. Immun. 82 2014 1268 1276
45. J.M. Voyich, and et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils J. Immunol. 175 2005 3907 3919
46. H.D. Gresham, and et al. Survival of Staphylococcus aureus inside neutrophils contributes to infection J. Immunol. 164 2000 3713 3722
47. B.G. Surewaard, and et al. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis Cell. Microbiol. 15 2013 1427 1437
48. A.M. Palazzolo-Balance, and et al. Neutrophil microbicides induce a pathogen survival response in community-associated methicillin-resistant Staphylococcus aureus J. Immunol. 180 2008 500 509
49. A.L. DuMont, and et al. Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils Infect. Immun. 81 2013 1830 1841
50. J.H. Melehani, and et al. Staphylococcus aureus leukocidin A/B (LukAB) kills human monocytes via host NLRP3 and ASC when extracellular, but not intracellular PLoS Pathog. 11 2015 e1004970
51. J.C. Lee, and et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats Infect. Immun. 65 1997 4146 4151
52. N. Malachowa, and et al. Staphylococcus aureus Leukotoxin GH promotes inflammation J. Infect. Dis. 206 2012 1185 1193
53. A.N. Spaan, and et al. The staphylococcal toxin Panton-Valentine Leukocidin targets human C5a receptors Cell Host Microbe. 13 2013 584 594
54. B. Loffler, and et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils PLoS Pathog. 6 2010 e1000715
55. C.Y.M. Okumura, and V. Nizet Subterfuge and sabotage: evasion of host innate defenses by invasive gram-positive bacterial pathogens Annu. Rev. Microbiol. 68 2014 439 458
56. T.J. Foster Immune evasion by staphylococci Nat. Rev. Microbiol. 3 2005 948 958
57. J.A. Sharp, and et al. Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic PLoS ONE 7 2012 e38407
58. K.L. Atkins, and et al. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation Mol. Immunol. 45 2008 1600 1611
59. R.J. Brezski, and R.E. Jordan Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs 2 2010 212 220
60. S.X. Xu, and J.K. McCormick Staphylococcal superantigens in colonization and disease Front. Cell. Infect. Microbiol. 2 2012 52
61. F. Alonzo 3rd, and V.J. Torres The bicomponent pore-forming leucocidins of Staphylococcus aureus Microbiol. Mol. Biol. Rev. 78 2014 199 230
62. M.M. van der Kooi-Pol, and et al. High anti-staphylococcal antibody titers in patients with epidermolysis bullosa relate to long-term colonization with alternating types of Staphylococcus aureus J. Invest. Dermatol. 133 2013 847 850
63. N. Hirschhausen, and et al. A novel staphylococcal internalization mechanism involves the major autolysin Atl and heat shock cognate protein Hsc70 as host cell receptor Cell Microbiol. 12 2010 1746 1764
64. K. Dutta, and et al. Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies J. Biol. Chem. 290 2015 6715 6730
65. J.J. Nienaber, and et al. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins J. Infect. Dis. 204 2011 704 713
66. X.G. Qiu, and et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Nature 514 2014 47
67. L.D. Hernandez, and et al. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling Antimicrob. Agents Chemother. 59 2015 1052 1060
68. F. Bagnoli, and et al. Composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus Proc. Natl. Acad. Sci. U.S.A. 112 2015 3680 3685
69. H. Rouha, and et al. Five birds, one stone: neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody MAbs 7 2015 243 254
70. H. Karauzum, and et al. Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome J. Biol. Chem. 287 2012 25203 25215
71. H.K. Kim, and et al. Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice Infect. Immun. 80 2012 3460 3470
72. V. Thammavongsa, and et al. Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus Vaccine 33 2015 523 526
73. J.J. Varrone, and et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters J. Orthop. Res. 32 2014 1389 1396
74. S. van den Berg, and et al. A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia Int. J. Med. Microbiol. 305 2015 55 64
75. Brown E.J. et al. Genentech Inc. Anti-wall teichoic antibodies and conjugates, WO 2014194247 A1
76. S.M. Lehar, and et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus Nature 527 2015 323 328
77. S.A. Jacobs, and et al. Design of novel FN3 domains with high stability by a consensus sequence approach Protein Eng. Des. Sel. 25 2012 107 117
78. M.D. Diem, and et al. Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions Protein Eng. Des. Sel. 27 2014 419 429
79. Torres, V.J. et al. New York University and Janssen Biotech Inc. Compositions and methods for phagocyte delivery of antistaphylococcal agents, 20150210756 A1
80. B.J. Laventie, and et al. Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins Proc. Natl. Acad. Sci. U.S.A. 108 2011 16404 16409